Crizotinib is branded as Xalkori, while Axitinib as Inlyta by Pfizer . Fresenius Kabi has informed its decision to withdraw four petitions against patent of Crizotinib and one against Axitinib with the Intellectual Property Appellate Board (IPAB) ... 4 Traders, 1 week ago
Pfizer : FRESENIUS KABI WITHDRAWS PATENT PLEAS AGAINST PFIZER - 4 Traders, 1 week ago
Fresenius Kabi withdraws patent pleas against Pfizer - Financial Express, 2 weeks ago
Cancer drug major Fresenius Kabi Oncology Ltd, the Indian arm of Germany-based Fresenius Kabi, has withdrew revocation petitions against cancer drug patents owned by Pfizer and its subsidiaries as the former has "lost business interest" in the molecules. The ...Business Standard, 2 weeks ago
@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma @EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury ...FiercePharma, 1 week ago
the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Busulfan Fresenius Kabi intended for conditioning treatment prior to conventional ...European Medicines Agency, 1 month ago Xultophy, Accofil and Busulfan recommended by EMA/CHMP Pharma Letter, 1 month ago News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014 European Medicines Agency, 1 month ago
Approval has been recommended for 2 new generic drugs that can be used in cancer treatment in the European Union, as has an expanded indication for a third drug. Marketing authorization has been recommended by the Committee for Medicinal Products ...American Journal of Public Health, 1 month ago
on your WebpageAdd Widget >Get your members hooked!